Demographic and clinical characteristics of study patients
| Characteristics . | Patients with cancer (%) n = 181 . | Patients without cancer (%) n = 661 . | P . |
|---|---|---|---|
| Age (mean ± SD) | 64.7 ± 11.4 | 60.1 ± 18.2 | .003 |
| Range | 31-90 | 15-96 | |
| Sex, M/F | 84/97 | 325/336 | |
| Patient-doctor delay* (d; median, range) | 7 (1-30) | 7 (1-30) | |
| Extent of thrombosis | |||
| Isolated calf | 11 (6.1) | 42 (6.3) | |
| Calf + popliteal | 15 (8.3) | 60 (9.1) | |
| Calf + popliteal + femoral | 63 (34.8) | 247 (37.4) | |
| All proximal veins | 82 (45.3) | 266 (40.2) | |
| Femoral and/or iliac | 10 (5.5) | 46 (6.9) | |
| Concomitant pulmonary embolism | 30 (16.6) | 92 (13.9) | |
| Additional risk factors | |||
| Chemotherapy | 36 (19.9) | NA | |
| Radiotherapy | 10 (5.5) | NA | |
| Recent trauma or surgery (<3 mo) | 55 (30.4) | 240 (36.3) | |
| Estrogen therapy | |||
| Pregnancy/childbirth | 6 (3.3) | 39 (5.9) | |
| 0 | 14 (2.1) | ||
| Initial treatment | |||
| Unfractionated heparin | 122 (67.4) | 442 (66.9) | |
| LMWH | 58 (32.0) | 216 (32.7) | |
| Thrombolytic drugs | 1 (0.5) | 3 (0.4) | |
| Length of oral anticoagulation | |||
| 6 mo or shorter | 79 (43.6) | 488 (73.8) | .001 |
| Longer than 6 mo | 102 (56.3) | 173 (26.2) | |
| Quality of oral anticoagulation | |||
| High quality | 137 (75.7) | 494 (74.7) | |
| Low quality | 44 (24.3) | 167 (25.3) |
| Characteristics . | Patients with cancer (%) n = 181 . | Patients without cancer (%) n = 661 . | P . |
|---|---|---|---|
| Age (mean ± SD) | 64.7 ± 11.4 | 60.1 ± 18.2 | .003 |
| Range | 31-90 | 15-96 | |
| Sex, M/F | 84/97 | 325/336 | |
| Patient-doctor delay* (d; median, range) | 7 (1-30) | 7 (1-30) | |
| Extent of thrombosis | |||
| Isolated calf | 11 (6.1) | 42 (6.3) | |
| Calf + popliteal | 15 (8.3) | 60 (9.1) | |
| Calf + popliteal + femoral | 63 (34.8) | 247 (37.4) | |
| All proximal veins | 82 (45.3) | 266 (40.2) | |
| Femoral and/or iliac | 10 (5.5) | 46 (6.9) | |
| Concomitant pulmonary embolism | 30 (16.6) | 92 (13.9) | |
| Additional risk factors | |||
| Chemotherapy | 36 (19.9) | NA | |
| Radiotherapy | 10 (5.5) | NA | |
| Recent trauma or surgery (<3 mo) | 55 (30.4) | 240 (36.3) | |
| Estrogen therapy | |||
| Pregnancy/childbirth | 6 (3.3) | 39 (5.9) | |
| 0 | 14 (2.1) | ||
| Initial treatment | |||
| Unfractionated heparin | 122 (67.4) | 442 (66.9) | |
| LMWH | 58 (32.0) | 216 (32.7) | |
| Thrombolytic drugs | 1 (0.5) | 3 (0.4) | |
| Length of oral anticoagulation | |||
| 6 mo or shorter | 79 (43.6) | 488 (73.8) | .001 |
| Longer than 6 mo | 102 (56.3) | 173 (26.2) | |
| Quality of oral anticoagulation | |||
| High quality | 137 (75.7) | 494 (74.7) | |
| Low quality | 44 (24.3) | 167 (25.3) |
Empty cells indicate not significant; NA, not applicable.
Delay from onset of DVT symptoms to start of anticoagulant therapy.